Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

NCT05857085 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Endothelial Dysfunction
Diabetes Mellitus, Type 1
Biomarkers
Endothelial Progenitor Cells
SGLT 2 Inhibitors
Incretins
Glucose Excursions
FMD
FPF
Arterial Stiffness

Interventions

DRUG: Semaglutide Pen Injector [Ozempic]
DRUG: Empagliflozin 10 MG

Sponsor

General and Teaching Hospital Celje